| 摘要 |
The present invention relates to a form 1 and form 2 polymorph of (-)-trans -3 -(5,6- dihydro-4-pyrrolo [3,2,1-] quinolin-1-yl)-4-(1-indol-3-yl) pyrrolidine-2,5-dione. The present invention also relates to (-)-trans-3-(5,6-dihydro-4-pyrrolo [3,2,1-] quinolin-1-yl)-4- (1-indol-3-yl) pyrrolidine-2, 5-dione compounds having a chiral purity greater than 99%, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising these (-)-trans-3-(5,6-dihydro-4-pyrrolo [3,2,1-] quinolin-l-yl)-4-(lH-indol-3-yl) pyrrolidine-2, 5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a composition comprising (-)-trans- 3-(5,6-dihydro-4H-pyrrolo [3,2,1-] quinolin-l-yl)-4-(l-indol-3-yl) pyrrolidine-2, 5-dione having a chiral purity greater than 99% or a form 1 and form 2 polymorph of (-)-trans -3 -(5,6- dihydro-4-pyrrolo [3,2,1-] quinolin-1-yl)-4-(1-indol-3-yl) pyrrolidine-2,5-dione. |
